SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

for the Quarterly Period Ended March 31, 2007

Commission file number 000-23731

NUTRACEUTICAL INTERNATIONAL CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		87-0515089
(State of incorporation)		(IRS Employer Identification No.)
1400 Kearns Boulevard, 2nd Floor, Park City, Utah		84060
(Address of principal executive office)		(Zip code)

(435) 655-6106

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES x NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer as defined in Rule 12b-2 of the Exchange Act (check one):

Large accelerated filer o

Accelerated filer x

Non-accelerated filer o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES o NO x

At April 26, 2007, the registrant had 11,020,804 shares of common stock outstanding.

NUTRACEUTICAL INTERNATIONAL CORPORATION

INDEX

Description			Page No.
Part I.	Financial Information		3
	Item 1.	Financial Statements	3
		Condensed Consolidated Balance Sheets -September 30, 2006 and March 31, 2007	3
		Condensed Consolidated Statements of Operations and Comprehensive Income - Three Months and Six Months Ended March 31, 2006 and 2007	4
		Condensed Consolidated Statements of Cash Flows -Six Months Ended March 31, 2006 and 2007	5
		Notes to Condensed Consolidated Financial Statements	6
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10
	Item 3.	Quantitative and Qualitative Disclosures about Market Risk	17
	Item 4.	Controls and Procedures	18
Part II.	Other Information		19
	Item 1.	Legal Proceedings	19
	Item 1A.	Risk Factors	19
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19
	Item 4.	Submission of Matters to a Vote of Security Holders	19
	Item 6.	Exhibits	20

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

NUTRACEUTICAL INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(dollars in thousands)

	September 30,			March 31,
	2006(1)			2007
ASSETS
Current assets
Cash		$	2,834	$	3,239
Accounts receivable, net		10,621		13,856
Inventories, net		27,329		26,656
Prepaid expenses and other current assets		1,882		2,497
Deferred income taxes		1,771		1,781
Total current assets		44,437		48,029
Property, plant and equipment, net		32,669		35,482
Goodwill		18,366		33,231
Intangible assets, net		6,755		9,818
Other non-current assets, net		630		594
Deferred income taxes, net		5,103		4,013
		$	107,960	$	131,167
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable		$	9,124	$	10,523
Accrued expenses		5,370		5,034
Total current liabilities		14,494		15,557
Long-term debt		2,500		17,000
Other non-current liabilities		184		191
Total liabilities		17,178		32,748
Stockholders’ equity
Common stock		110		110
Additional paid-in capital		32,665		32,769
Retained earnings		57,840		65,354
Accumulated other comprehensive income		167		186
Total stockholders’ equity		90,782		98,419
		$	107,960	$	131,167

(1) The condensed consolidated balance sheet as of September 30, 2006 has been prepared using information from the audited financial statements at that date.

The accompanying notes are an integral part of these condensed consolidated financial statements.

NUTRACEUTICAL INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME
(unaudited)
(dollars in thousands, except per share data)

	Three months ended March 31,					Six months ended March 31,
	2006			2007		2006			2007
Net sales	$	41,025		$	42,104	$	77,729		$	77,952
Cost of sales	19,272			18,980		36,832			35,304
Gross profit	21,753			23,124		40,897			42,648
Operating expenses
Selling, general and administrative	14,485			16,036		27,931			29,958
Amortization of intangible assets	94			63		188			109
Income from operations	7,174			7,025		12,778			12,581
Interest and other (income)/expense, net	(1,020		)	318		(1,031		)	462
Income before provision for income taxes	8,194			6,707		13,809			12,119
Provision for income taxes	3,154			2,548		5,316			4,605
Net income	$	5,040		$	4,159	$	8,493		$	7,514
Other comprehensive income/(loss)
Foreign currency translation adjustment, net of tax	5			25		(5		)	19
Comprehensive income	$	5,045		$	4,184	$	8,488		$	7,533
Net income per common share
Basic	$	0.44		$	0.38	$	0.74		$	0.68
Diluted	0.43			0.37		0.73			0.67
Weighted average common shares outstanding
Basic	11,407,900			11,018,748		11,439,865			11,017,342
Dilutive effect of stock options	185,703			221,917		175,174			209,118
Diluted	11,593,603			11,240,665		11,615,039			11,226,460

The accompanying notes are an integral part of these condensed consolidated financial statements.

NUTRACEUTICAL INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(dollars in thousands)

	Six months ended March 31,
	2006			2007
Cash flows from operating activities
Net income	$	8,493		$	7,514
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	2,338			2,265
Amortization of deferred financing fees	91			28
Losses/(gain) on disposals of property and equipment	(1,100		)	4
Deferred income taxes	597			612
Changes in assets and liabilities, net of effects of acquisitions
Accounts receivable, net	(2,499		)	(2,818		)
Inventories, net	(3,588		)	2,283
Prepaid expenses and other current assets	365			(580		)
Other non-current assets, net	6			(3		)
Accounts payable	806			1,254
Accrued expenses	(418		)	(417		)
Other non-current liabilities	—			(49		)
Net cash provided by operating activities	5,091			10,093
Cash flows from investing activities
Acquisitions of businesses	(95		)	(20,064		)
Proceeds from sale of property and equipment	4,500			—
Purchases of property and equipment	(9,896		)	(4,221		)
Net cash used in investing activities	(5,491		)	(24,285		)
Cash flows from financing activities
Payments on other non-current liabilities	(225		)	—
Proceeds from long-term debt	6,000			20,500
Payments on long-term debt	(5,000		)	(6,000		)
Proceeds from issuances of common stock	140			86
Purchases of common stock for treasury	(1,969		)	—
Tax benefit from stock option exercises	10			18
Net cash provided by (used in) financing activities	(1,044		)	14,604
Effect of exchange rate changes on cash	(2		)	(7		)
Net increase (decrease) in cash	(1,446		)	405
Cash at beginning of period	3,371			2,834
Cash at end of period	$	1,925		$	3,239

The accompanying notes are an integral part of these condensed consolidated financial statements.

NUTRACEUTICAL INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(dollars in thousands, except per share data)

1. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all necessary adjustments (consisting of normal recurring accruals) to present fairly the consolidated financial position of Nutraceutical International Corporation and its subsidiaries (the “Company”) as of March 31, 2007, the results of their operations for the three months and six months ended March 31, 2006 and 2007 and their cash flows for the six months ended March 31, 2006 and 2007, in conformity with accounting principles generally accepted in the United States of America for interim financial information applied on a consistent basis. Results for the three and six months ended March 31, 2007 are not necessarily indicative of the results to be expected for the full fiscal year.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted. Accordingly, these financial statements should be read in conjunction with the Company’s Form 10-K for the Fiscal Year Ended September 30, 2006, which was filed with the Securities and Exchange Commission on November 30, 2006.

2. ACCOUNTS RECEIVABLE, NET

Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following:

	September 30,				March 31,
	2006				2007
Accounts receivable		$	12,610			$	15,904
Less allowances		(1,989		)		(2,048		)
		$	10,621			$	13,856

3. INVENTORIES, NET

Inventories, net of reserves for slow moving, obsolete and/or damaged inventory, were comprised of the following:

	September 30,				March 31,
	2006				2007
Raw materials		$	11,712			$	10,997
Work-in-process		6,415				6,163
Finished goods		11,104				11,396
		29,231				28,556
Less reserves		(1,902		)		(1,900		)
		$	27,329			$	26,656

4. ACQUISITION

On January 10, 2007, the Company acquired the Zand®, Natra-Bio®, bioAllers®, Herbs for Kids™ and Complimed® brands by purchasing selected operating assets of Botanical Laboratories, Inc.

NUTRACEUTICAL INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
(dollars in thousands, except per share data)

The aggregate purchase price of this acquisition was approximately $8,674 in cash. The Consolidated Statements of Operations and Consolidated Statements of Cash Flows presented herein include the activities of this acquired business from the date of acquisition. The expected long-term sales and expense synergies of acquired businesses are generally not realized immediately following acquisition as certain transition and integration matters must be completed.

This acquisition is in keeping with the Company’s business strategy of consolidating the fragmented industry in which it competes. The acquisition was accounted for using the purchase method of accounting. Accordingly, the aggregate purchase price was assigned to the assets acquired and liabilities assumed based on their fair market values at the date of acquisition. The excess of aggregate purchase price over the fair market values of the assets acquired and liabilities assumed was classified as goodwill. The following reflects the allocation of the aggregate purchase price for this acquisition to the aggregate assets acquired and liabilities assumed:

Current assets	$	507
Goodwill	7,191
Intangible assets	976
	$	8,674

The acquired intangible assets of $976, which include trademarks and tradenames that have indefinite lives and are not subject to amortization, and goodwill of $7,191, which is not subject to amortization for financial statement purposes, are expected to be deductible for tax purposes over fifteen years.

5. PROPERTY, PLANT AND EQUIPMENT

On January 20, 2006, the Company sold its 31,340 square foot building located in Park City, Utah for approximately $4,500 in cash. At the time of sale, the building had a book value of $3,395. A gain of $1,105 ($680 after tax, or $0.06 per diluted share) was included in interest and other (income)/expense for the three and six months ended March 31, 2006.

6. GOODWILL

The change in the carrying amount of goodwill from September 30, 2006 to March 31, 2007 was as follows:

	Goodwill
Balance as of September 30, 2006	$	18,366
Goodwill attributable to fiscal 2007 acquisitions	14,865
Balance as of March 31, 2007	$	33,231

NUTRACEUTICAL INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
(dollars in thousands, except per share data)

7. INTANGIBLE ASSETS

The carrying amounts of intangible assets at September 30, 2006 and March 31, 2007 were as follows:

	September 30, 2006										March 31, 2007										Weighted
	Gross							Net			Gross							Net			Average
	Carrying			Accumulated				Carrying			Carrying			Accumulated				Carrying			Amortization
	Amount			Amortization				Amount			Amount			Amortization				Amount			Period (Years)
Intangible assets subject to amortization:
Trademarks/trade names/patents		$	361		$	(284	)		$	77		$	425		$	(305	)		$	120		5
Customer relationships		—			—				—			457			(24		)		433			8
Developed software and technology		—			—				—			772			(64		)		708			5
		361			(284		)		77			1,654			(393		)		1,261
Intangible assets not subject to amortization:
Trademarks/trade names/licenses		6,678			—				6,678			8,557			—				8,557
		$	7,039		$	(284	)		$	6,755		$	10,211		$	(393	)		$	9,818

Estimated future amortization expense related to the March 31, 2007 net carrying amount of $1,261 for intangible assets subject to amortization is as follows:

	Estimated
	Amortization
Year Ending September 30,	Expense
2007(1)		$	125
2008		244
2009		241
2010		234
2011		227
Thereafter		190
		$	1,261

(1) Estimated amortization expense for the year ending September 30, 2007 includes only amortization to be recorded after March 31, 2007.

8. OPERATING SEGMENTS

Segment identification and selection is consistent with the management structure used by the Company to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company does not review operating results on a disaggregated basis; rather, management reviews operating results on an aggregate basis.

NUTRACEUTICAL INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
(dollars in thousands, except per share data)

Net sales attributed to customers in the United States and foreign countries for the three and six months ended March 31, 2006 and 2007 were as follows:

	Three months ended March 31,				Six months ended March 31,
	2006		2007		2006		2007
United States	$	37,237	$	37,800	$	70,430	$	70,093
Foreign countries	3,788		4,304		7,299		7,859
	$	41,025	$	42,104	$	77,729	$	77,952

Certain net sales attributed to customers in the United States are sold to customers who in turn may sell such products to customers in foreign countries while certain net sales attributed to customers in foreign countries are sold to customers who in turn may sell such products to customers in the United States.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

General

The following discussion and analysis should be read in conjunction with this report on Form 10-Q, including Part I, Item 1.

We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. Our core business strategy is to acquire, integrate and operate, from beginning to end, the manufacturing, marketing and distribution of branded nutritional supplement businesses in the natural products industry. We believe that the consolidation and integration of these acquired businesses provides ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

We sell branded nutritional supplements and other natural products under the trademarks Solaray® , KAL®, Nature’s Life®, Natural Balance®, NaturalMax®, VegLife®, Premier One®, Pioneer®, CompliMed®, Sunny Green®, Zand®, Natra-Bio®, bioAllers®, Herbs for Kids™, Natural Sport®, Supplement Training Systems™, FunFresh Foods™, ActiPet®, Action Labs®, Thompson®, Montana Big Sky™, Body Gold®, Healthway®, Living Flower Essences®, Life-flo®, Larenim®, AllVia™, Sayge BioSciences™, Monarch Nutritional Laboratories™ and Great Basin Botanicals™. Under the name Woodland Publishing™, we publish, print and market a line of books and booklets to, among others, book distributors, national retail bookstores and health and natural food stores. We also distribute branded products of certain third parties.

We own neighborhood natural food markets, which operate under the trade names The Real Food Company ™, Thom’s Natural Foods™ and Cornucopia Community Market™. We also own health food stores, which operate under the trade names Arizona Health Foods™, Fresh Vitamins™, Granola’s™ and Pilgrim’s Natureway™.

We were formed in 1993 by senior management and Bain Capital, Inc. to effect a consolidation strategy in the fragmented vitamin, mineral, herbal and other nutritional supplements industry (the “VMS Industry”). Since our formation, we have completed the following acquisitions: Solaray, Inc.; Premier One Products, Inc.; Makers of KAL, Inc. and Makers of KAL, B.V.; Monarch Nutritional Laboratories, Inc.; Action Labs, Inc.; NutraForce (Canada) International, Inc.; Woodland Publishing, Inc. and Summit Graphics, Inc.; Thompson Nutritionals, Inc.; The Real Food Company, Inc.; Thom’s Natural Foods; M.K. Health Food Distributors, Inc. (dba Nature’s Life); Arizona Health Foods, Inc.; Natural Balance, Inc.; Montana Naturals, Inc.; Cornucopia Community Market, Inc.; Pilgrim’s Natureway LLC; Pioneer Nutritional Formulas, Inc.; Living Flower Essences LLC; Life-flo Health Care Products, Inc. and Nutraceutical Labs, Inc.; Vitamin Outlet, Inc. (dba Larenim) and Botanical Laboratories, Inc. As a result of these acquisitions, internal growth and cost management, we believe that we are well positioned to continue to capitalize on acquisition opportunities that arise in the VMS Industry.

Critical Accounting Policies

The preparation of our financial statements in conformity with accounting principles generally accepted in the United States of America required us to make estimates and assumptions that affected the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Significant estimates included values and lives assigned to acquired intangible assets, reserves for customer returns and allowances, uncollectible accounts receivable and slow moving and obsolete and/or damaged inventory. Actual results may differ from these estimates.

Our estimates and judgments related to our critical accounting policies, including factors and assumptions considered in making these estimates and judgments, did not vary significantly for the periods presented and had no material impact on the consolidated financial statements as reported. Our critical accounting policies include the following:

Accounts Receivable—Provision is made for estimated bad debts based on periodic analysis of individual customer balances, including an evaluation of days sales outstanding, payment history, recent payment trends and perceived credit worthiness. If general economic conditions and/or customer financial condition were to change, additional provisions for bad debts may be required, which could have a material impact on the consolidated financial statements.

Inventories—Provision is made for slow moving, obsolete and/or damaged inventory based on periodic analysis of individual inventory items, including an evaluation of historical usage and/or movement, age, expiration date and general condition. If market demand and/or consumer preferences are less favorable than historical trends or future expectations, additional provisions for slow moving, obsolete and/or damaged inventory may be required, which could have a material impact on the consolidated financial statements.

Property, Plant and Equipment—Depreciation and amortization expense is impacted by our judgments regarding the estimated useful lives of assets placed in service. If the actual lives of assets are significantly less than expected, depreciation and amortization expense would be accelerated, which could have a material impact on the consolidated financial statements.

Goodwill and Intangible Assets—Statement of Financial Accounting Standards No. 141, Business Combinations, and Statement of Financial Accounting Standards No. 142, Goodwill and Other Intangible Assets (“SFAS 142”), require estimates and judgments in determining the initial recognition and measurement of goodwill and intangible assets, including factors and assumptions used in determining fair values and useful lives. Intangible assets with finite useful lives are amortized, while intangible assets with indefinite useful lives are not amortized. In addition, SFAS 142 requires ongoing, periodic impairment testing, which relies on such factors and assumptions as identified reporting units, as well as expected future net cash flows relative to recorded book values. If an asset impairment were identified, a loss would be recorded, which could have a material impact on the consolidated financial statements.

Revenue Recognition—Revenue is recognized in accordance with Staff Accounting Bulletin No. 104, Revenue Recognition, which states that revenue should be recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the product has been shipped and the customer takes ownership and assumes the risk of loss; (3) the selling price is fixed or determinable; and (4) collection of the resulting receivable is reasonably assured. We believe that these criteria are satisfied upon shipment from our facilities or, in the case of our neighborhood natural food markets and health food stores, at the point of sale within these stores. Revenue is reduced by provisions for estimated returns and allowances, which are based on historical averages that have not varied significantly for the periods presented, as well as specific known claims, if any. No other significant deductions from revenue must be estimated at the point in time that revenue is recognized.

Results of Operations

The following table sets forth certain consolidated statements of operations data as a percentage of net sales for the periods indicated:

	Three months ended March 31,				Six months ended March 31,
	2006		2007		2006		2007
Net sales	100.0	%	100.0	%	100.0	%	100.0	%
Cost of sales	47.0	%	45.1	%	47.4	%	45.3	%
Gross profit	53.0	%	54.9	%	52.6	%	54.7	%
Selling, general and administrative	35.3	%	38.1	%	35.9	%	38.4	%
Amortization of intangible assets	0.2	%	0.1	%	0.3	%	0.2	%
Income from operations	17.5	%	16.7	%	16.4	%	16.1	%
Interest and other (income)/expense, net	(2.5	)%	0.8	%	(1.3	)%	0.6	%
Income before provision for income taxes	20.0	%	15.9	%	17.7	%	15.5	%
Provision for income taxes	7.7	%	6.0	%	6.8	%	5.9	%
Net income	12.3	%	9.9	%	10.9	%	9.6	%
EBITDA(1)	20.4	%	19.4	%	19.4	%	19.0	%

(1) See “—EBITDA.”

Comparison of the Three Months Ended March 31, 2007 to the Three Months Ended March 31, 2006

Net Sales. Net sales increased by $1.1 million, or 2.6%, to $42.1 million for the three months ended March 31, 2007 (“second quarter of fiscal 2007”) from $41.0 million for the three months ended March 31, 2006 (“second quarter of fiscal 2006”). Net sales of branded nutritional supplements and other natural products increased by $1.2 million, or 3.1%, to $37.8 million for the second quarter of fiscal 2007 compared to $36.6 million for the second quarter of fiscal 2006. The increase in net sales of branded nutritional supplements and other natural products was primarily related to the net sales contributions of the fiscal 2007 acquired businesses, partially offset by a decrease in sales of some SKUs of branded products to certain customers. Other net sales remained relatively flat at $4.3 million for the second quarter of fiscal 2007 compared to $4.4 million for the second quarter of fiscal 2006. Management believes that the VMS Industry continues to have low growth rates and remains very competitive.

Gross Profit. Gross profit increased by $1.3 million, or 6.3%, to $23.1 million for the second quarter of fiscal 2007 from $21.8 million for the second quarter of fiscal 2006. This increase in gross profit was primarily attributable to the increase in net sales. As a percentage of net sales, gross profit increased to 54.9% for the second quarter of fiscal 2007 compared to 53.0% for the second quarter of fiscal 2006. This increase in gross profit was primarily attributable to decreased material costs as a percentage of net sales, including some changes in sales mix related to the fiscal 2007 acquisitions.

Selling, General and Administrative. Selling, general and administrative expenses increased by $1.5 million, or 10.7%, to $16.0 million for the second quarter of fiscal 2007 from $14.5 million for the second quarter of fiscal 2006. As a percentage of net sales, selling general and administrative expenses increased to 38.1% for the second quarter of fiscal 2007 compared to 35.3% for the second quarter of fiscal 2006. This increase in selling, general and administrative expenses was primarily attributable to operating costs related to the fiscal 2007 acquired businesses, as well as costs that tend to be fixed in the short term for sales of certain products to certain customers, which sales were below management’s expectations.

Amortization of Intangibles. Amortization of intangibles was approximately $0.1 million for the second quarter of fiscal 2007 and 2006. For each period, amortization expense was primarily related to intangible assets recorded in connection with acquisitions.

Interest and Other (Income)/Expense, Net. Net interest and other (income)/expense for the second quarter of fiscal 2006 included other income of $1.1 million ($0.7 million after tax, or $0.06 per diluted share) related to the gain on the sale of our 31,340 square foot building located in Park City, Utah. Exclusive of this gain, net interest and other (income)/expense was $0.3 million for the second quarter of fiscal 2007 and $0.1 million for the second quarter of fiscal 2006 and primarily consisted of interest expense on indebtedness under our revolving credit facility.

Provision for Income Taxes. Our effective tax rate was 38.0% for the second quarter of fiscal 2007 and 38.5% for the second quarter of fiscal 2006. In each period, our effective tax rate was higher than the federal statutory rate primarily due to state taxes.

Comparison of the Six Months Ended March 31, 2007 to the Six Months Ended March 31, 2006

Net Sales. Net sales increased by $0.3 million, or 0.3%, to $78.0 million for the six months ended March 31, 2007 from $77.7 million for the six months ended March 31, 2006. Net sales of branded nutritional supplements and other natural products increased by $0.4 million, or 0.5%, to $69.4 million for the six months ended March 31, 2007 compared to $69.0 million for the six months ended March 31, 2006. The increase in net sales of branded nutritional supplements and other natural products was primarily related to the net sales contributions of the fiscal 2007 acquired businesses, partially offset by a decrease in sales of some SKUs of branded products to certain customers. Other net sales remained relatively flat at $8.6 million for the six months ended March 31, 2007 compared to $8.7 million for the six months ended March 31, 2006. Management believes that the VMS Industry continues to have low growth rates and remains very competitive.

Gross Profit. Gross profit increased by $1.7 million, or 4.3%, to $42.6 million for the six months ended March 31, 2007 from $40.9 million for the six months ended March 31, 2006. As a percentage of net sales, gross profit increased to 54.7% for the six months ended March 31, 2007 compared to 52.6% for the six months ended March 31, 2006. This increase in gross profit was primarily attributable to decreased material costs as a percentage of net sales, including some changes in sales mix related to the fiscal 2007 acquisitions, as well as the increase in net sales.

Selling, General and Administrative. Selling, general and administrative expenses increased by $2.1 million, or 7.3%, to $30.0 million for the six months ended March 31, 2007 from $27.9 million for the six months ended March 31, 2006. As a percentage of net sales, selling general and administrative expenses increased to 38.4% for the six months ended March 31, 2007 compared to 35.9% for the six months ended March 31, 2006. This increase in selling, general and administrative expenses was primarily attributable to operating costs related to the fiscal 2007 acquired businesses, as well as costs that tend to be fixed in the short term for sales of certain products to certain customers, which sales were below management’s expectations.

Amortization of Intangibles. Amortization of intangibles was $0.1 million for the six months ended March 31, 2007 compared to $0.2 million for the six months ended March 31, 2006. For each period, amortization expense was primarily related to intangible assets recorded in connection with acquisitions.

Interest and Other (Income)/Expense, Net. Net interest and other (income)/expense for the six months ended March 31, 2006 included other income of $1.1 million ($0.7 million after tax, or $0.06 per diluted share) related to the gain on the sale of our 31,340 square foot building located in Park City, Utah as well as $0.1 million for payments received as settlement of litigation to which we were a plaintiff. Exclusive of these items, net interest and other (income)/expense was $0.5 million for the six months ended March 31, 2007 and $0.2 million for the six months ended March 31, 2006 and primarily consisted of interest expense on indebtedness under our revolving credit facility.

Provision for Income Taxes. Our effective tax rate was 38.0% for the six months ended March 31, 2007 and 38.5% for the six months ended March 31, 2006. In each period, our effective tax rate was higher than the federal statutory rate primarily due to state taxes.

EBITDA

EBITDA (a non-GAAP measure) is defined as earnings before net interest and other (income)/expense, taxes, depreciation and amortization. EBITDA has some inherent limitations in measuring operating performance due to the exclusion of certain financial elements such as depreciation and amortization and is not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the method of calculation. Furthermore, EBITDA is not intended to be a substitute for cash flows from operating activities, as a measure of liquidity, or an alternative to net income in determining our operating performance in accordance with generally accepted accounting principles. Our use of EBITDA should be considered within the following context:

· We acknowledge that plant and equipment (while less important in our line of business due to outsourcing alternatives) are necessary to earn revenue based on our current business model.

· Our use of EBITDA as a measure of operating performance is not based on any belief about the reasonableness of excluding depreciation and amortization when measuring financial performance.

· Our use of EBITDA is supported by the importance of EBITDA to the following key stakeholders:

· Analysts—who estimate our projected EBITDA and other EBITDA-based metrics in their independently developed financial models for investors;

· Creditors—who evaluate our operating performance based on compliance with certain EBITDA-based debt covenants;

· Investment Bankers—who use EBITDA and other EBITDA-based metrics in their written evaluations and comparisons of companies within our industry; and

· Board of Directors and Executive Management—who use EBITDA as an essential metric for evaluating management performance relative to our operating budget and bank covenant compliance, as well as our ability to service debt and raise capital for growth opportunities, including acquisitions, which are a critical component of our stated strategy. Historically, we have recorded a monthly accrual for incentive compensation as a percentage of EBITDA, which has been paid out to executive management, as well as other employees, upon completion of our annual audit.

The following table sets forth a reconciliation of net income to EBITDA for each period included herein:

	Three months ended March 31,					Six months ended March 31,
	2006			2007		2006			2007
Net income	$	5,040		$	4,159	$	8,493		$	7,514
Provision for income taxes	3,154			2,548		5,316			4,605
Interest and other (income)/expense, net(1)	(1,020		)	318		(1,031		)	462
Depreciation and amortization	1,197			1,164		2,338			2,265
EBITDA	$	8,371		$	8,189	$	15,116		$	14,846

(1) Includes amortization of deferred financing fees and losses associated with fixed asset disposals. The three and six months ended March 31, 2006 also include a gain of $1,105 on the sale of a building, which gain is excluded in determining EBITDA.

Our EBITDA decreased to $8.2 million for the second quarter of fiscal 2007 from $8.4 million for the second quarter of fiscal 2006. EBITDA as a percentage of net sales decreased to 19.4% for the second quarter of fiscal 2007 from 20.4% for the second quarter of fiscal 2006.

Our EBITDA decreased to $14.8 million for the six months ended March 31, 2007 from $15.1 million for the six months ended March 31, 2006. EBITDA as a percentage of net sales decreased to 19.0% for the six months ended March 31, 2007 from 19.4% for the six months ended March 31, 2006.

Seasonality

We believe that our business is characterized by minor seasonality. However, sales to any particular customer can vary substantially from one quarter to the next based on such factors as industry trends, timing of promotional discounts, international economic conditions and acquisition-related activities. Excluding the effect of acquisitions, we have historically recorded higher branded products sales volume during the second fiscal quarter (January thru March) due to increased interest in health-related products among consumers following the holiday season.

Liquidity and Capital Resources

We had working capital of $32.5 million as of March 31, 2007 compared to $29.9 million as of September 30, 2006. This increase in working capital was primarily the result of increases in cash, accounts receivable and prepaid expenses and other current assets and a decrease in accrued expenses, partially offset by a decrease in inventories and an increase in accounts payable.

Net cash provided by operating activities for the six months ended March 31, 2007 was $10.1 million compared to $5.1 million for the comparable period in fiscal 2006. This increase in net cash provided by operating activities for the six months ended March 31, 2007 was primarily attributable to an increase in cash provided by changes in assets and liabilities, net of effects of acquisitions.

Net cash used in investing activities was $24.3 million for the six months ended March 31, 2007 compared to $5.5 million for the comparable period in fiscal 2006. Our investing activities during these periods consisted of acquisitions of businesses, capital expenditures and, for the six months ended March 31, 2006, proceeds of $4.5 million related to the sale of our building.

During the six months ended March 31, 2007, we made four acquisitions. On October 31, 2006, we acquired a majority interest in a complementary natural products business. On November 15, 2006, we acquired the Life-flo® brand of health care products, which includes therapeutic creams sold in health and natural food stores, by purchasing substantially all of the operating assets of Life-flo Health Care Products, Inc. and Nutraceutical Labs, Inc. On December 15, 2006, we acquired the Larenim® brand of mineral makeup by purchasing certain assets of Vitamin Outlet, Inc. On January 10, 2007, we acquired the Zand®, Natra-Bio®, bioAllers®, Herbs for Kids™ and Complimed® brands by purchasing certain operating assets of Botanical Laboratories, Inc. These acquisitions are in keeping with our business strategy of consolidating the fragmented industry where we compete and give us nutritional brands with products we currently do not sell.

The aggregate purchase price of these acquisitions was approximately $20.1 million in cash, which was financed primarily using borrowings under our revolving credit facility. The expected long-term sales and expense synergies of acquired businesses are generally not realized immediately following acquisition as certain transition and integration matters must be completed.

Capital expenditures during these periods related primarily to real estate, distribution and manufacturing equipment, building improvements related to facility consolidation efforts and information systems.

Net cash provided by (used in) financing activities was $14.6 million for the six months ended March 31, 2007 compared to ($1.0) million for the comparable period in fiscal 2006. During these periods, financing activities primarily related to borrowings and repayments under our revolving credit facility, purchases of common stock for treasury and proceeds from the issuance of common stock.

Our current revolving credit facility has available credit borrowings of $60.0 million with no automatic reductions and provides an accordion feature which can increase the available credit borrowings to $90.0 million, subject to approval by the lenders and compliance with certain covenants and conditions.

At March 31, 2007, we had outstanding revolving credit borrowings of $17.0 million. Borrowings under the revolving credit facility are collateralized by substantially all our assets. At our election, borrowings under the revolving credit facility bear interest at the applicable Eurodollar Rate plus a variable margin or at a base rate, which is the higher of the Federal Funds Rate plus 0.5% or the Prime Lending Rate, plus a variable margin. At March 31, 2007, the applicable weighted-average interest rate for borrowings was 6.10%. We are also required to pay a variable quarterly fee on the unused balance under the revolving credit facility. At March 31, 2007, the applicable rate was 0.18%. Accrued interest on Eurodollar Rate borrowings is payable based on elected intervals of one, two or three months. Accrued interest on base rate borrowings is payable quarterly. The revolving credit facility matures on September 7, 2011, and we are required to repay all principal outstanding under the revolving credit facility on such date.

The revolving credit facility contains restrictive covenants, including limitations on incurring certain other indebtedness and requirements that we maintain certain financial ratios. As of March 31, 2007, we were in compliance with these restrictive covenants. Upon the occurrence of a default, the lender has various remedies or rights, which may include proceeding against the collateral or requiring us to repay all amounts outstanding under the revolving credit facility.

A key component of our business strategy is to seek to make additional acquisitions, which may require that we obtain additional financing, which could include the incurrence of substantial additional indebtedness or the issuance of additional stock. We believe that borrowings under our current revolving credit facility or a replacement credit facility, together with cash flows from operations, will be sufficient to make required payments under the current credit facility or any such replacement facility, and to make anticipated capital expenditures and fund working capital needs for fiscal 2007.

Our significant non-cancelable contractual obligations as of March 31, 2007 were as follows:

	Payments Due By Period
	(dollars in thousands)
Contractual Obligations	Total		Less Than 1 Year			1-3 Years		4-5 Years		After 5 Years
Revolving credit facility	$	17,000		$	—	$	—	$	17,000		$	—
Interest on revolving credit facility(a)	5,076			1,142		2,285		1,649			—
Operating leases	5,015			2,161		1,801		967			86
Total	$	27,091		$	3,303	$	4,086	$	19,616		$	86

(a) Represents estimated interest obligations associated with our outstanding revolving credit facility balance of $17.0 million at March 31, 2007, assuming no principal payments are made before maturity, a weighted-average interest rate of 6.10% and an underutilization fee rate of 0.18%.

New Accounting Standards

The Financial Accounting Standards Board issued Interpretation No. 48, Accounting for Uncertainty in Income Taxes (“FIN 48”) in June 2006. The interpretation clarifies the accounting for uncertainty in income taxes recognized in financial statements in accordance with SFAS 109. FIN 48 is effective for fiscal

years beginning after December 15, 2006. We have not determined the effect, if any, the adoption of FIN 48 will have on our consolidated financial statements.

We periodically review new accounting standards that are issued from time to time. Although some of these accounting standards may be applicable to us, we have not identified any other new standards that we believe merit further discussion, and we expect that none would have a significant impact on our consolidated financial statements.

Inflation

Inflation affects the cost of raw materials, goods and services used by us. In recent years, inflation has been modest. The competitive environment somewhat limits our ability to recover higher costs resulting from inflation by raising prices. We seek to mitigate the adverse effects of inflation primarily through improved productivity and cost containment programs. We do not believe that inflation has had a material impact on our results of operations for the periods presented, except with respect to increased costs in manufacturing, packaging and distribution resulting from increased fuel and other petrochemical costs, as well as payroll-related costs, insurance premiums and other costs arising from or related to government imposed regulations.

Forward-Looking Statements

This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, level of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these statements. We undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date this Form 10-Q was first filed with the SEC. Important factors that may cause results to differ from these forward-looking statements include, but are not limited to, government regulations, product liability claims and litigation, insurance coverage issues, a decrease in or slowing of the growth rate of the vitamin, mineral and supplement market, the success of the healthy foods channel, consumer perception of the safety and quality of our products and similar products, competition, intellectual property rights of other parties, the loss of key personnel, disruptions from acquisitions, issues with obtaining raw materials of adequate quality or quantity, problems with information management systems, manufacturing efficiencies and operations, litigation generally, the volatility of the stock market generally and of our stock specifically, a general lack of adequate industry analyst coverage, and other factors indicated from time to time in our SEC reports, copies of which are available upon request from our investor relations group or which may be obtained at the SEC’s website (www.sec.gov).

Item 3. Quantitative and Qualitative Disclosures about Market Risk

At our election, borrowings under our revolving credit facility bear interest at the applicable Eurodollar Rate plus a variable margin or at a base rate, which is the higher of the Federal Funds Rate plus 0.5% or the Prime Lending Rate, plus a variable margin. At March 31, 2007, the applicable weighted-average interest rate for borrowings was 6.10% and we had total borrowings outstanding of $17.0 million. To date, we have not obtained interest rate protection with respect to these borrowings.

With respect to our international operations, we are subject to currency fluctuations; however, we do not believe that these fluctuations would have a material adverse impact on our financial position because the majority of our net sales to foreign countries are transacted in U.S. dollars. To date, we have not hedged any of our potential foreign currency exposures.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate, to allow for timely decisions regarding required disclosure.

In designing and evaluating the disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and we are required to apply our judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision of and with the participation of our management, including our principal executive and principal financial officers, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our principal executive and principal financial officers have concluded that our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting. There were no changes in our internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

As discussed in our other filings, we are subject to regulation by a number of federal, state and foreign agencies and are involved in various legal matters arising in the normal course of business.

We carry insurance coverage in the types and amounts that we consider reasonably adequate to cover the risks we face in the industry in which we compete. However, our current liability policy excludes claims related to certain ingredients, including products containing ephedra.

In our opinion, the outcomes of individual regulatory and legal matters in which we are presently involved are not probable and no estimate can be made of the range of potential gains or losses. While incapable of estimation, in the opinion of management, the individual regulatory and legal matters in which we are involved are not expected to have a material adverse effect on our consolidated financial position, results of operations or cash flows.

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in our 2006 Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

We did not sell any unregistered equity securities nor did we repurchase any shares of our common stock during the period covered by this Form 10-Q for the Quarterly Period Ended March 31, 2007.

Item 4. Submission of Matters to a Vote of Security Holders

The Annual Meeting of Stockholders of the Company was held on January 26, 2007, at which meeting the stockholders voted to elect two individuals to serve as Class III Directors of the Company and to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditors for the fiscal year ending September 30, 2007.

The nominees for election as Class III Directors of the Company are listed below. The results were as follows:

Nominee	For	Against/ Withheld		Abstain
Frank W. Gay II	10,287,512		59,469	671,323
Gregory M. Benson	10,251,237		95,744	671,323

The names of other Directors of the Company whose term of office continued after the meeting are as follows:

Micheal D. Burke

J. Kimo Esplin

Jeffrey A. Hinrichs

James D. Stice

Other matters voted upon at the meeting and the results of those votes were as follows:

	For	Against/ Withheld		Abstain
Ratification of PricewaterhouseCoopers LLP as the Company’s independent auditors	10,256,176		82,965	679,163

Item 6. Exhibits

31.1		Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certifications Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NUTRACEUTICAL INTERNATIONAL CORPORATION (Registrant)
Date: April 26, 2007	By:	/s/ Leslie M. Brown, Jr.
		Leslie M. Brown, Jr.
		Senior Vice President, Finance, Chief Financial Officer and Assistant Secretary
		(Principal Financial and Accounting Officer)